Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Viva Biotech to Pay $368 Million to Acquire Controlling Stake in China CDMO

publication date: Aug 10, 2020

Viva Biotech, a Shanghai structure-based drug discovery CRO, will pay $368 million to acquire an 80% stake in Zhejiang Langhua Pharma, a CDMO and API company. Viva said the acquisition will add services that transform Viva into a one-stop biotech CRO platform. Viva offers its structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide via two models: cash-for-service (CFS) or equity-for service (EFS), which includes investment and incubation services for high-potential biotech start-ups. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here